[Vibravenös in infections of the biliary and respiratory tracts (author's transl)].
The clinical results of a European Vibravenös multicentre trial are reported as far as 227 patients with infections of the biliary tract and 185 patients with infections of the respiratory tract--mainly pneumonia--are concerned. In 203 of the 227 cases with biliary tract infections (=90%) and in 142 of the 185 cases with respiratory tract infections (=77%) the overall clinical result was good or very good. Toleration of Vibravenös was usually very good, only 4 patients had to be withdrawn from the trial because of side effects: in 3 cases an allergic skin reaction or pruritus occurred and in 1 patient local phlebitis developed at the injection site. Bacteriological tests performed on 71 patients showed that after broad usage doxycycline has an excellent antibacterial activity.
D000328:Adult; D000368:Aged; D001660:Biliary Tract Diseases / Q000188:drug therapy*; D004318:Doxycycline / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003875:Drug Eruptions / Q000209:etiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010689:Phlebitis / Q000139:chemically induced; D011014:Pneumonia / Q000188:drug therapy; D011537:Pruritus / Q000139:chemically induced; D012141:Respiratory Tract Infections / Q000188:drug therapy*
D004318:Doxycycline
Vibravenös bei Gallenweg- und Atemweginfektionen